ALDH1A1 level and activity are upregulated in patients treated with neoadjuvant chemotherapy and are associated with extreme chemoresistance and poor prognosis in pancreatic cancer and beyond. This evidence concerns the gene ALDH1A1 and familial pancreatic carcinoma.